AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) provided a business update and reported financial results for the three and nine months ended September 30, 2016. Corporate Highlights …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and investigators will be presenting two e-posters at the European Congress on Emergency Medicine (ECEM), …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced the initiation of the Phase 3 IAP312 study of Zalviso® (sufentanil sublingual tablet system), an investigational product candidate being …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that Dr. Shankar Lakshman, a board-certified plastic surgeon and AcelRx clinical investigator, will present a subgroup analysis from …
AcelRx Pharmaceuticals Inc’s (NASDAQ:ACRX) just announced positive top-line results from its third, final Phase 3 trial of pipeline drug ARX-04 designed to treat …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) will announce the results of its multicenter, open-label Phase 3 clinical study of ARX-04, known as SAP303. The study …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and its investigators will be presenting results from the Phase 3 SAP302 study of ARX-04 (sufentanil …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, …
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today …
Abercrombie & Fitch Co. (NYSE:ANF) is down close to 12% in pre-market trading after the firm released disappointing 1Q:16 earnings this morning.